| Literature DB >> 35605029 |
Xi Tan1, Yi-Pin Lin2, Michael J Pereira3, Mildred Castellanos1, Beth L Hahn4, Phillip Anderson4, Jenifer Coburn4, John M Leong3, George Chaconas5.
Abstract
Hematogenous dissemination is a critical step in the evolution of local infection to systemic disease. The Lyme disease (LD) spirochete, which efficiently disseminates to multiple tissues, has provided a model for this process, in particular for the key early event of pathogen adhesion to the host vasculature. This occurs under shear force mediated by interactions between bacterial adhesins and mammalian cell-surface proteins or extracellular matrix (ECM). Using real-time intravital imaging of the Lyme spirochete in living mice, we previously identified BBK32 as the first LD spirochetal adhesin demonstrated to mediate early vascular adhesion in a living mouse; however, deletion of bbk32 resulted in loss of only about half of the early interactions, suggesting the existence of at least one other adhesin (adhesin-X) that promotes early vascular interactions. VlsE, a surface lipoprotein, was identified long ago by its capacity to undergo rapid antigenic variation, is upregulated in the mammalian host and required for persistent infection in immunocompetent mice. In immunodeficient mice, VlsE shares functional overlap with OspC, a multi-functional protein that displays dermatan sulfate-binding activity and is required for joint invasion and colonization. In this research, using biochemical and genetic approaches as well as intravital imaging, we have identified VlsE as adhesin-X; it is a dermatan sulfate (DS) adhesin that efficiently promotes transient adhesion to the microvasculature under shear force via its DS binding pocket. Intravenous inoculation of mice with a low-passage infectious B. burgdorferi strain lacking both bbk32 and vlsE almost completely eliminated transient microvascular interactions. Comparative analysis of binding parameters of VlsE, BBK32 and OspC provides a possible explanation why these three DS adhesins display different functionality in terms of their ability to promote early microvascular interactions.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35605029 PMCID: PMC9166660 DOI: 10.1371/journal.ppat.1010511
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 7.464
Fig 4Intravital imaging to investigate microvascular interactions of VlsE in gain of functions strains.
A) Intravital imaging micrograph of B. burgdorferi in a post-capillary venule of mouse knee joint (see for strain info). An infectious GFP-expressing B. burgdorferi B31 strain (GCB726) was injected into the tail vein of BALB/c mice. Vascular adhesion interactions were detected by high acquisition rate spinning disk confocal intravital microscopy 5 min post-infection. Blood vessels were stained with Alexa Fluor 647 anti-mouse CD31 (PECAM-1) antibody, shown in red. B) The effect of VlsE (GCB3023) and VlsEECM (GCB3025) on transient microvascular interactions in a B31-A background (see ). The control strain lacking VlsE was GCB3212. After infection, the number of interactions/minutes in transient adhesion interactions were analyzed using intravital microscopy (see Materials and Methods). Error bars represent SD and statistical significance was analyzed using the non-parametric two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli (n = 4 mice). C) Clearance of B. burgdorferi from the vasculature. Clearance of B. burgdorferi from the vasculature in the mice used in panel B was monitored by withdrawal of blood through the tail vein at 3- and 18-minutes post-inoculation as described in [8] and spirochetes number in the plasma were counted by dark-field microscopy. The data are plotted as the percentage of spirochetes in plasma at 18 minutes relative to the 3 minutes time point for each mouse.
Bacterial strains used.
| Strain number | Background/ Reference |
|
| Description | Borrelia plasmid Content | Antibiotic resistance | Source/ Reference |
|---|---|---|---|---|---|---|---|
|
| |||||||
| GCB909 | B31-A [ | N/A | [ | ||||
| GCB919 | B31-5A17 [ | lp25-, lp28- | [ | ||||
| GCB3022 | B31-A3 [ | cp9- | [ | ||||
|
| |||||||
| GCB705 | B31-A [ | B31-A + pTM61 | GmR 100 μg/ml | [ | |||
| GCB726 | 5A4 NP1 [ | 5A4 NP1 ( | KmR 200 μg/ml | [ | |||
| GCB3023 | B31-A [ | B31-A + pTM61 | N/A | SmR 50 μg/ml | This work | ||
| GCB3025 | B31-A [ | B31-A + pTM61 | N/A | SmR 50 μg/ml | This work | ||
| GCB3212 | B31-A [ | B31-A + pTM61 | SmR 50 μg/ml | [ | |||
| GCB4036 | B31-5A17 [ |
|
| lp25-, lp28-, Δ | lp25-, lp28-, cp9- | KmR 200 μg/ml | This work |
| GCB4043 | B31-5A17 [ |
|
| lp25-, lp28-, + pTM61 | lp25-, lp28-, cp9- | KmR 200 μg/ml | This work |
| GCB4080 | B31-5A17 [ |
|
| lp25-, lp28-, + pTM61 | lp25-, lp28-, cp9 | KmR 200 μg/ml | This work |
| GCB4082 | B31 5A17 [ |
|
| lp25-, lp28-, Δ | lp25-, lp28-, cp9 | KmR 200 μg/ml SmR 50 μg/ml | This work |
| GCB4452 | B31-A3 | B31-A3 Δ | cp9- | GmR 100 μg/ml | [ | ||
| GCB4458 | B31-A3 | B31-A3 Δ | lp28-4-, lp56-, cp9- | GmR 100 μg/ml | [ | ||
| GCB4465 | B31-5A17 [ |
|
| lp25-, lp28-, + | lp25-, lp28-, lp38-, cp9- | SmR 50 μg/ml | This work |
| GCB4517 | B31-5A17 [ |
|
| lp25-, lp28-, Δ | lp25-, lp28-, cp9- | KmR 200 μg/ml SmR 50 μg/ml | This work |
|
| |||||||
| MP01 | DH5α [ | DH5α + pGEX4T2, | AmpR 100 μg/ml | This work | |||
| MP02 | DH5α [ | DH5α + pGEX4T2, | AmpR 100 μg/ml | This work | |||
| MP03 | BL21(DE3) [ | BL21(DE3) + pGEX4T2, | AmpR 100 μg/ml | This work | |||
| MP04 | BL21(DE3) [ | BL21(DE3) + pGEX4T2, | AmpR 100 μg/ml | This work | |||
| YLT153 | BL21(DE3) [ | BL21(DE3) + pGEX4T2, amp, | AmpR 100 μg/ml | [ | |||
| GCE3823 | DH5α [ | pMC117 ( | AmpR 100 μg/ml | This work | |||
| GCE3828 | DH5α [ | pTM61 | KmR 50 μg/ml | This work | |||
| GCE3951 | DH5α [ | pTM61 | KmR 50 μg/ml | This work | |||
| GCE3970 | DH5α [ | KmR 50 μg/ml | This work | ||||
| GCE3993 | DH5α [ | pTM61 | KmR 50 μg/ml | This work | |||
| GCE3994 | DH5α [ | KmR 50 μg/ml | This work | ||||
| GCE4001 | DH5α [ | AmpR 100 μg/ml | This work | ||||
| GCE4004 | DH5α [ | pTM61 | KmR 50 μg/ml | This work |
Long-term mouse infections with wild-type and vlsE and bbk32 mutants.
Infection of SCID mice inoculated with B. burgdorferi strains GCB4036, GCB4080, GCB4082, and GCB4517 (see Table 1) was assessed at three weeks post-inoculation by culture. Shown are the number of mice infected at each of two disseminated sites over the number of mice inoculated for each dose and B. burgdorferi strain.
| PBS | GCB 4080 | GCB 4036 | GCB 4517 | GCB 4082 | |||
|---|---|---|---|---|---|---|---|
| Bbk32 | + | - | - | - | |||
| dose delivered | tissue cultured | VlsE | + | - | + | VlsEECM | |
| bladder | 0/5 | ||||||
| ear | 0/5 | ||||||
| 103 bacteria | bladder | 0/5 | 1/5 | 0/5 | 1/5 | ||
| ear | 0/5 | 1/5 | 0/5 | 1/5 | |||
| 105 bacteria | bladder | 5/5 | 5/5 | 4/5 | 5/5 | ||
| ear | 5/5 | 5/5 | 4/5 | 5/5 | |||
| 107 bacteria | bladder | 5/5 | 5/5 | ND | 5/5 | ||
| ear | 5/5 | 5/5 | ND | 5/5 |
*Not determined. This set of mice was lost to a mechanical failure in the animal facility.
Comparison of ligand binding parameters for OspC, VlsE and BBK32.
The values noted are for proteins from B. burgdorferi B31 and are taken from the following sources: OspC, [14]; VlsE, this work; BBK32 (residues 45–68) and BBK32 (residues 108–205), [49]. The BBK32 proteins that were included for the kinetic parameters here are the fragments of the amino acids 45–68 and 108–205, which are the DS- and FN-binding domains of BBK32.
| Protein | KD (μM) | kon (104s-1M-1) | koff (s-1) |
|---|---|---|---|
| OspC / DS | 0.57 ± 0.17 | 1.71 ± 0.17 | 0.01 ± 0.004 |
| VlsE / DS | 0.51 ± 0.05 | 60.3 ± 7.5 | 0.31 ± 0.01 |
| BBK32 (45–68) / DS | 0.23 ± 0.039 | 14.5 ± 0.17 | 0.03 ± 0.17 |
| BBK32 (108–205) / FN | 0.018 ± 0.001 | 398 ± 0.15 | 0.072 ± 0.002 |